but cddp runs the risk of renal and myelotoxicity , so we studied renal dysfunction after treatment by examining serum and urinary beta 2-microglobulin ( beta 2-m ) , and rbc , hb , wbc , lymphocyte , and plt .
C0014792
rbc
C0019046
hb